Introduction: There is some evidence regarding the role of LAG-3, TLR mediated neuroinflammation in PD.
Methods: sLAG-3, TOLLIP, NLRP3 levels were measured in PD and healthy controls.
Results: These markers were significantly higher in PD and were associated with progression.
Conclusion: sLAG3 and TOLLIP are involved in the NLRP3 mediated inflammatory activation in PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.parkreldis.2021.09.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional and phenotypic changes in natural killer cells expressing immune checkpoint receptors PD-1, CTLA-4, LAG-3, and TIGIT in non-small cell lung cancer: the comparative analysis of tumor microenvironment, peripheral venous blood, and tumor-draining veins.
Immunol Res
December 2024
Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Natural killer (NK) cells are a cytotoxic subset of innate lymphoid cells and have key roles in antitumoral immunity. This study evaluates the roles of immune checkpoint receptors on NK cell phenotype and functions both before and after circulation through tumor tissue. Twenty non-small cell lung cancer patients undergoing surgery and 21 healthy controls were included.
View Article and Find Full Text PDFT-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome.
Open Forum Infect Dis
November 2024
Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
Background: Co-inhibitory receptors (immune checkpoints) regulate activated immune cells. Their expression on T cells can limit host defense. We hypothesized that chronic infection in patients with visceral leishmaniasis (VL) leads to expression of co-inhibitory receptors that could be markers of treatment response and clinical outcome.
View Article and Find Full Text PDFThe FGL-1/LAG-3 Axis is Associated With Disease Course in Alcohol-associated Hepatitis: A Preliminary Report.
J Clin Exp Hepatol
October 2024
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Background: Alcohol-associated hepatitis (AH) has a short-term mortality rate of up to 40% primarily related to impaired hepatocyte regeneration and uncontrolled liver inflammation. The acute phase protein fibrinogen-like protein 1 (FGL-1) produced by hepatocytes stimulates hepatocyte proliferation by autocrine signaling. FGL-1 also is a ligand for the inhibitory T cell receptor lymphocyte activation gene 3 (LAG-3).
View Article and Find Full Text PDFSoluble immune checkpoints associated with disease activity and treatment response in GD and TED.
J Clin Endocrinol Metab
October 2024
Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Context: Soluble immune checkpoints play an important role in peripheral tolerance that has seldom been investigated in Graves' disease (GD) and thyroid eye disease (TED).
Objective: The objective of this work is to examine the alteration of soluble immune checkpoints in GD and TED.
Methods: We performed a quantitative multiplex analysis of 17 immune checkpoint proteins in serum from 50 GD patients without TED, 28 GD patients with TED and 40 healthy controls.
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.
JTO Clin Res Rep
November 2024
Research and Development, Immutep S.A.S., Saint-Aubin, France.
Article Synopsis
- Eftilagimod alpha (efti) is a protein that activates immune cells, potentially overcoming resistance to PD-(L)1 inhibitors, and was tested with pembrolizumab on NSCLC patients who had previously failed anti-PD-(L)1 therapy.
- In a study of 36 patients, efti was administered alongside pembrolizumab, with primary focus on the objective response rate and secondary measures including overall survival and disease control.
- Results showed modest activity with an 8.3% objective response rate and a median overall survival of 9.9 months, particularly benefiting patients with higher PD-(L)1 expression, while the treatment was well-tolerated without severe adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!